SCHEMBL1205991

SCHEMBL1205991

CCCN(CCC)Cc1ccc(NCc2ccc(CN)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 2/20 0.51
▸ MAPT P10636 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ CASP1 P29466 2/20 0.42
▸ BLM P54132 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ APAF1 O14727 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ RORC P51449 3/20 0.42
▸ CNR2 P34972 1/20 0.41
▸ TPSAB1 Q15661 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13078725 0.85 HRH3 (0.69) HRH3MAPT
SCHEMBL1206261 0.76 HDAC6 (0.59) MEN1POLBKMT2ARORCKDM4E
SCHEMBL1205938 0.76 CXCR4 (0.50) HRH3MAPTMEN1ALDH1A1POLB
SCHEMBL27881777 0.74 MAPT (0.67) MAPTMEN1ALDH1A1POLBGAA
SCHEMBL9726439 0.74 HRH3 (0.64) HRH3MAPTRORCKDM4E
SCHEMBL1206283 0.74 HRH3 (0.64) HRH3MAPTRORC
SCHEMBL2203383 0.74 MAPT (0.57) HRH3MAPT
SCHEMBL1206332 0.74 RPS6KA2 (0.52) RORCHDAC1HDAC7
SCHEMBL1205392 0.74 CXCR4 (0.53) HRH3MAPTMEN1ALDH1A1POLB
SCHEMBL1206737 0.73 HRH3 (0.53) HRH3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-02-24 — — US disclosed
US-7833991-B2 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2010-11-16 — — US disclosed
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2007-09-06 — — US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 — — US disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 — — US disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 HRH3 57/4885MAPT 3413/4885MEN1 1206/4885
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF NR0B2, NR1D2, NR0B1 HRH3 54/4885MAPT 3600/4885MEN1 721/4885
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists CXCR4, CXCR6, CCR5 HRH3 66/4885MAPT 4739/4885MEN1 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback